Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
This study is to find out the safety and effectiveness of Avonex (interferon-beta-1a) Therapy
in patients who have developed neutralizing antibodies during previous interferon-beta
treatment